2. Search Result
Search Result
Results for "

spontaneously hypertensive rats

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Peptides

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113986
    Dexfadrostat

    (R)-Fadrozole; (R)-CGS 16949A free base; FAD286

    		 Others Cardiovascular Disease
    Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor . Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats. .
    Dexfadrostat
  • HY-N4209
    3α-Dihydrocadambine

    		Others Cardiovascular Disease
    3α-Dihydrocadambine is a natural product isolated from the heartwoods of Anthocephalus cadamba.3α-Dihydrocadambine exhibits dose-dependent hypotensive and anti-hypertensive effects in anesthetized normotensive rats and in conscious spontaneously hypertensive rats .
    3α-Dihydrocadambine
  • HY-116680
    LY53857

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-116262
    SCH 51866

    		Phosphodiesterase (PDE) Cardiovascular Disease Inflammation/Immunology
    SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC50=70 nM) and PDE5 (IC50=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC50=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension .
    SCH 51866
  • HY-19053
    NP-252

    		Calcium Channel Cardiovascular Disease
    NP-252 is a calcium channel antagonist with an 20% effective dose (ED20) of 2.55 mg/kg in spontaneously hypertensive rats .
    NP-252
  • HY-121417
    Laserpitin

    		Others Cardiovascular Disease Metabolic Disease
    Laserpitin, a coumarin, increases serum HDL levels, especially apoE-HDL, and decreases the hepatic triglyceride content in stroke-prone spontaneously hypertensive rats (SHRSP) .
    Laserpitin
  • HY-155042
    Antihypertensive agent 3

    		Angiotensin Receptor Cardiovascular Disease
    Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensin II receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .
    Antihypertensive agent 3
  • HY-129706
    LY127210 free base

    		Others Cardiovascular Disease
    LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .
    LY127210 free base
  • HY-136880
    Flufylline

    Sgd 195/78

    		 5-HT Receptor Cardiovascular Disease
    Flufylline shows antihypertensive properties in spontaneously hypertensive rats and display antagonism towards 5-HT receptors in various animal models. Flufylline can be used for cardiovascular disease research .
    Flufylline
  • HY-127152
    Hippadine

    Pratorine

    		 Endogenous Metabolite Cardiovascular Disease
    Hippadine (Pratorine) is an alkaloid, which can be isolated from the plant Crinum macowanii. Hippadine exhibits heart-rate lowering and blood-pressure lowering effects in rats models with spontaneously hypertensive .
    Hippadine
  • HY-P4296
    H-Gly-Sar-Sar-OH

    		Amino Acid Derivatives Others
    H-Gly-Sar-Sar-OH is an orally active tripeptide. H-Gly-Sar-Sar-OH is transported through PepT1 within Caco-2 cells. H-Gly Sar Sar OH has potential applications in material transportation .
    H-Gly-Sar-Sar-OH
  • HY-121550
    ME3221

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    ME3221 is an angiotensin AT1 receptor antagonist that effectively antagonizes the pressor response to angiotensin II in rats and marmosets without affecting the hypotensive response to bradykinin. It demonstrates potent antihypertensive effects in renal hypertensive rats and spontaneously hypertensive rats (SHR), with efficacy comparable to or better than losartan in vivo. ME3221's repeated administration in SHR results in sustained and stable hypotensive effects without affecting heart rate, indicating its potential for treating both renal and essential hypertension similarly to losartan .
    ME3221
  • HY-107398
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride

    		Others Cardiovascular Disease
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride is a phenylethanolamine N-methyltransferase (PNMT) inhibitor. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride effectively reduces blood pressure of spontaneously hypertensive. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride can be used for the research of blood pressure .
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride
  • HY-A0117
    Temocaprilat

    Temocapril diacid; Temocaprilate; RS 5139

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation .
    Temocaprilat
  • HY-103247B
    EMD-66684 potassium salt

    		Angiotensin Receptor Cardiovascular Disease
    EMD-66684 potassium salt is a non-peptide angiotensin II receptor antagonist that demonstrates significant antihypertensive effects in spontaneously hypertensive rats. EMD-66684 potassium salt exhibits nanomolar affinity for angiotensin II receptors, comparable to losartan in potency. EMD-66684 potassium salt shows increased activity when modified with acetamides, leading to superior blood pressure reduction.
    EMD-66684 potassium salt
  • HY-153369
    BAY-747

    		Guanylate Cyclase Cardiovascular Disease Neurological Disease
    BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
    BAY-747
  • HY-100554
    BMY 7378

    		Adrenergic Receptor 5-HT Receptor Cardiovascular Disease
    BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist .
    BMY 7378
  • HY-106720
    Amosulalol

    YM 09538

    		 Adrenergic Receptor Cardiovascular Disease
    Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .
    Amosulalol
  • HY-106720A
    Amosulalol hydrochloride

    YM 09538 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    Amosulalol (YM 09538) hydrochloride is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol hydrochloride exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol hydrochloride decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .
    Amosulalol hydrochloride
  • HY-111827
    S-1-Propenyl-L-cysteine
    5 Publications Verification

    		 Histamine Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology
    S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model . S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway . S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine
  • HY-101390A
    (-)-Niguldipine hydrochloride

    (R)-Niguldipine hydrochloride

    		 Calcium Channel Cardiovascular Disease
    (-)-Niguldipine ((R)-Niguldipine) hydrochloride is a calcium channel antagonist. (-)-Niguldipine hydrochloride exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (-)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID50 of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (Ki of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED30 of 5.55). (-)-Niguldipine hydrochloride can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias .
    (-)-Niguldipine hydrochloride
  • HY-W013989
    1,3-Dicyclohexylurea

    		Epoxide Hydrolase Cardiovascular Disease
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats .
    1,3-Dicyclohexylurea
  • HY-103247
    EMD 66684

    		Angiotensin Receptor Cardiovascular Disease
    EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
    EMD 66684
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-B0592R
    Trandolapril (Standard)

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril (Standard)
  • HY-B0592A
    Trandolapril hydrochloride

    RU44570 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril hydrochloride
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: